Tags : Second

Eli Lilly to Initiate P-I Study of its Second Antibody

Shots: Lilly’s partner Junshi has dosed the first healthy volunteer in a study evaluating JS016 to combat COVID-19. The study is being conducted by Junshi in China while Lilly to imminently initiate its P-I study in the US Both P-I studies aim to evaluate the safety, tolerability, PK and immunogenicity of JS016 in healthy participants […]Read More

Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to

Shots: Saniona to receive up to $84.6 as milestones along with royalties on sales of the therapies. Boehringer Ingelheim to get an exclusive global right to research, develop, manufacture and commercialize therapeutics, identified under the collaboration The focus of the collaboration is to identify new therapies for schizophrenia by utilizing Saniona’s ion channel drug discovery […]Read More

Kite Reports Submission of BLA to the US FDA for

Shots: The Kite has submitted BLA to the US FDA for its investigational CAR T cell therapy, KTE-X19 for the treatment of r/r MCL The BLA submission is based on P-II ZUMA-2 study assessing KTE-X19 in 74 patients aged ≥18 yrs. with r/r MCL prior treated with up to 5L therapies, demonstrating ORR (93%); CR […]Read More

Roche Reports Results of Satralizumab in Second P-III Study for

Shots: The second P-III SAkuraStar study involves assessing of Satralizumab (120 mg) as monothx. vs PBO in97 patients in a ratio (2:1) with AQP4-IgG seropositive or seronegative NMO and AQP4-IgG seropositive NMOSD aged 20-70yrs. The P-III SAkuraStar study results: 55% & 74% reduction in risk of relapse in overall population & AQP4-IgG seropositive patients; relapse […]Read More

Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3

Shots: The P-III MONALEESA-3 study involves assessing of Kisqali (ribociclib) + fulvestrant in postmenopausal women with HR+/HER2- advanced or m-breast cancer The second phase of P-III MONALEESA-3 study resulted in meeting its 2EPs of OS with no new observed safety signals and consistent AEs with the previous P-III study results. These results follow MONALEESA-7 study results […]Read More

PharmaShots’ Key Highlights of Second Quarter 2019

The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate revenue with addition of Allergan’s medical aesthetics and ophthalmology portfolio. Prior to that, Pfizer acquired Array Biopharma for $11.4B to expand its oncology portfolio. Some […]Read More